Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
about
Temozolomide for children and adolescents with diffuse intrinsic pontine gliomaNew chemotherapy strategies and biological agents in the treatment of childhood ependymomaFeasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium studyPhase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyTemozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportCentral nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour ConsortiumMoving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.Invasiveness of pharmacokinetic studies in children: a systematic reviewA pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.Pediatric CNS tumors: current treatment and future directions.Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Molecular therapeutic targets for glioma angiogenesis.Risk-adapted chemotherapy in childhood medulloblastoma.Treatment of high-grade glioma in children and adolescents.Metronomics: towards personalized chemotherapy?A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.A Multifuntional Nanoplatform Based on Responsive Fluorescent Plasmonic ZnO-Au@PEG Hybrid Nanogels
P2860
Q24200164-82DE0EE6-539E-4999-A303-DB211D31AC86Q24658324-EA43FBB0-173D-4172-A322-BF7C8FB4C0DCQ33391731-C7A782E3-1F20-426D-BE82-F0DEB8D338D3Q33406813-DBB0FE8E-914F-4467-8F6C-6CF1B9EED64AQ33409117-5E3E4921-0441-4602-9D91-2C3F28CC887BQ33413067-9C89DC6F-8028-434F-8E11-EAC331C2A480Q33415790-D4CFFC91-641F-4200-892D-AEDF88F3EF1FQ33729396-5BE186AC-53DC-4D95-B737-50647E8CB449Q34344177-4C2216FC-0C84-4B18-9A8A-D8C34C7DC559Q34541456-E510B1A4-8709-44B7-BC62-12DFDEDB8F34Q35116804-06322346-2C49-4651-B0C8-FD5850F9830FQ36081153-CB9A4709-04B6-488A-94D6-0B959220E38DQ36615612-DC439AE2-52F1-4A9E-ABB5-E942003CB6D6Q36902043-0B4F5B97-B569-4028-8E76-AD457991303CQ37255687-30713CE9-DC3B-4ED9-A247-829A882C0C96Q37369556-572677EE-BC4E-4C87-B09C-2A38E0DED259Q37528441-F39C6879-2B16-4EAA-AEBC-FC74FAFEF1E9Q37564201-6335A0CC-33EA-4342-BEC4-54FF870CFC88Q37736281-FF8F9B84-FF6B-45C8-8E8D-2D86FDD12A5BQ37873471-D1CD32E7-65B4-4E7D-9EF2-961131E74842Q37904503-2FC73C27-3F4B-433E-A427-843F0A5E7665Q38218923-6381FE30-C7A4-4B6D-AA80-223B8CEC4A53Q38373115-2E658795-79A2-464F-BA29-9B79655F80E3Q38638654-3589A60E-7E0B-49F3-BFB8-53A43465D565Q39501053-C9528B8E-FE45-4018-83FA-2ECD003EA767Q44596535-4CD07D1F-EA8F-483B-9F76-B38C15936005Q46188537-C4F12B86-9B82-47C8-BAC4-6A5EBE84B6F1Q47133403-BCD4D974-18F9-4200-B84D-8279A8C0999CQ54412464-DC600B31-B796-4863-B0E2-1C5CB95AB967Q57346806-307FA239-99B2-4709-B0F9-90B87E2D3EBF
P2860
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@ast
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@en
type
label
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@ast
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@en
prefLabel
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@ast
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@en
P2093
P1476
Safety and pharmacokinetics of ...... rent paediatric brain tumours.
@en
P2093
A Moghrabi
C V Fernandez
S Baruchel
P304
P356
10.1016/J.EJCA.2006.03.023
P577
2006-08-08T00:00:00Z